Research ArticleCancer

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

See allHide authors and affiliations

Science Translational Medicine  13 Mar 2019:
Vol. 11, Issue 483, eaaq1238
DOI: 10.1126/scitranslmed.aaq1238

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Lung cancer finding its sensitive side

Mutations in an oncogene called KRAS are common in a variety of tumor types, including lung cancer, and these tumors are often difficult to treat. In addition to tumor genetics, tumor cell phenotype plays a role in treatment resistance, and tumor cells that have converted from an epithelial to a mesenchymal phenotype are less likely to respond to chemotherapy. Peng et al. examined signaling alterations that occur during the epithelial-to-mesenchymal transition and identified a pathway that could be targeted by the epigenetic drug mocetinostat, restoring sensitivity to chemotherapy in cancer cells and mouse models.